Formulating for Menopausal Skin: Barrier Resilience, Structural  Integrity and Skin Longevity Approaches

Menopause represents a distinct physiological stage characterized by endocrine  changes that significantly influence skin biology. Declining estrogen levels affect  epidermal barrier function, extracellular matrix (ECM) maintenance, hydration,  inflammatory signalling and oxidative balance, resulting in xerosis, increased  sensitivity, impaired barrier function, reduced elasticity and accelerated visible aging.  ¹^-³ 

Unlike chronological aging, menopause-associated skin changes are directly linked  to hormonal alterations. Estrogen receptors are distributed throughout the epidermis,  dermis and hair follicles, where they regulate lipid synthesis, fibroblast activity,  collagen production and wound healing. Estrogen receptor β (ERβ) predominates  within cutaneous tissues and appears to influence collagen homeostasis,  inflammatory regulation and epidermal differentiation. ¹^,² 

As women spend a substantial proportion of their lives in the postmenopausal  period, maintaining skin function, resilience and structural integrity has become  increasingly important. Contemporary formulation approaches are therefore moving  beyond conventional anti-aging paradigms toward strategies that preserve barrier  function, support extracellular matrix integrity and promote skin longevity. 

Menopause-Associated Skin Biology 

The stratum corneum relies on a highly organized lipid matrix consisting primarily of  ceramides, cholesterol and free fatty acids (FFAs) to regulate permeability and water  retention. Declining estrogen levels may impair lipid synthesis, contributing to  increased trans epidermal water loss (TEWL), xerosis and compromised barrier  function.⁴^,⁵ 

Estrogen also regulates fibroblast activity and extracellular matrix turnover. Reduced  estrogen levels may contribute to decreased collagen synthesis, accelerated matrix  degradation and diminished dermal thickness, resulting in reduced elasticity, wrinkle  formation and slower wound repair. ²^,³ 

In addition, menopause is associated with increased oxidative stress, altered  inflammatory signalling and heightened skin sensitivity. These physiological changes  indicate that menopause-focused formulations should address: 

• Epidermal barrier function  

• Hydration and lipid replenishment  

• Extracellular matrix maintenance  

• Oxidative stress 

• Inflammatory regulation  

• Long-term skin resilience  

Barrier Resilience and Epidermal Function 

Barrier dysfunction is among the most consistently reported characteristics of  menopausal skin. Ceramides are among the best-supported ingredients for barrier  repair, with clinical and ex vivo studies demonstrating improvements in lipid  organization and reductions in TEWL, particularly when combined with cholesterol  and FFAs. ⁴^,⁵ 

Biomimetic lipid systems designed to mimic the native stratum corneum have gained  increasing attention as strategies for restoring epidermal function. 

Humectants remain central to hydration strategies. Glycerin supports water retention  and barrier recovery, while multi-molecular-weight hyaluronic acid systems may  provide hydration at both superficial and deeper skin layers. ⁴ 

Squalane serves as a lightweight emollient with favorable sensory properties, while  ectoin functions as an Osmo protectant capable of protecting cells against  environmental stress. 

Barrier-focused positioning has become increasingly prominent within skincare.  Mintel GNPD data indicate that facial skincare launches referencing barrier-related claims increased from 8% during 2020–2021 to 19% during 2024–2025, reflecting  growing recognition of epidermal resilience as a key determinant of skin health. 

Niacinamide as a Multifunctional Active 

Niacinamide represents one of the most versatile ingredients for menopausal skin  because it addresses several menopause-associated biological changes  simultaneously. 

At concentrations typically ranging from 2–5%, niacinamide may:

• Stimulate ceramide synthesis
• Improve epidermal barrier function
• Reduce TEWL
• Increase natural moisturizing factor (NMF) production
• Improve pigmentation irregularities
• Support epidermal lipid synthesis  

Because menopausal skin frequently exhibits both barrier impairment and uneven  pigmentation, niacinamide offers multiple mechanisms of action within a single  ingredient platform. Its ability to influence ceramide production and epidermal  differentiation makes it particularly relevant for menopause-focused formulations. 

Structural Integrity and Extracellular Matrix Support 

Declining estrogen levels influence collagen synthesis and extracellular matrix  turnover, contributing to reduced firmness and elasticity. ² 

Peptides have attracted considerable interest because of their ability to influence  collagen-associated pathways and support extracellular matrix maintenance.  Emerging peptide technologies include: 

• Signal peptides  

• Gluco-peptides  

• Barrier-support peptides  

• Prebiotic peptides  

Recent patent activity increasingly positions peptides as multifunctional ingredients  capable of supporting both extracellular matrix maintenance and epidermal  resilience. 

Retinoids remain among the most extensively studied cosmetic actives forinsta_photos at Adobe Stock epidermal  renewal and dermal remodelling. However, increased skin sensitivity during  menopause frequently necessitates lower concentrations and improved delivery systems.

Microencapsulation technologies and co-formulation with barrier-support ingredients  may improve tolerability. 

Antioxidants including sodium ascorbyl phosphate, tetrahexyldecyl ascorbate,  vitamin E and coenzyme Q10 may further support skin resilience by reducing  oxidative stress.⁶^,⁷ 

Emerging Ingredient Pathways 

Recent patent activity has highlighted several ingredients with potential relevance to  menopause-associated skin concerns. 

Isoflavones and Phytoestrogen-Inspired Ingredients 

Isoflavone-containing botanical systems have been investigated for their potential  effects on estrogen-related pathways and skin appearance. Some phytoestrogens  may demonstrate selective estrogen receptor modulator (SERM)-like activity;  however, topical evidence remains limited and clinical outcomes are generally  modest. ¹³ 

Ergothioneine 

Ergothioneine, a naturally occurring sulfur-containing antioxidant derived from  mushrooms, has attracted interest because of its role in cellular protection and  oxidative stress reduction. 

Astragalus membranaceus 

Botanical extracts such as Astragalus membranaceus have been investigated in  relation to healthy aging and estrogen-associated pathways, although menopause specific clinical evidence remains limited. 

Because these ingredients may interact with hormone-related pathways, formulators  should exercise caution regarding efficacy claims and regulatory compliance. 

Sleep, Circadian Repair and Neurocutaneous Signaling 

Sleep disturbances frequently accompany menopause and may significantly affect  skin physiology, inflammatory responses and barrier recovery. 

Recent patents have explored ingredients such as mushroom extracts, theanine and  botanical actives to support overnight skin repair, hydration and skin comfort. 

The skin-brain axis has emerged as an important area of investigation. Current  approaches seek to: 

• Reduce stress-related neuropeptides  

• Modulate neuroinflammatory pathways  

• Support oxytocin and endorphin signaling 

• Improve barrier recovery  

• Enhance perceived skin comfort  

Many neurocosmetic approaches currently focus on sensory well-being and short term comfort. However, robust long-term clinical evidence evaluating barrier function  and skin physiology remains limited. 

Europe currently represents the largest market for neuro-related skincare claims,  indicating increasing commercial interest in skin-brain approaches. 

Yuliia at Adobe Stock

Microbiome and Skin Homeostasis 

The skin microbiome contributes to immune regulation, epidermal homeostasis and  barrier function.⁸^,⁹ 

Evidence for menopause-specific microbiome alterations remains preliminary. Most  studies are observational and may be influenced by anatomical site, hygiene  practices and topical product use. 

Nevertheless, declining estrogen levels may influence skin pH and sebum  composition, which may subsequently affect microbial diversity and epidermal  homeostasis. Changes in pH and lipid composition may influence microbial  communities, suggesting a potential role for microbiome-supportive formulations. 

Prebiotics, postbiotics and fermented ingredients are increasingly investigated for  their ability to support barrier function and skin homeostasis; however, menopause specific clinical evidence remains limited. 

Innovation and Patent Landscape 

Patent activity increasingly supports barrier and longevity-focused approaches. 

Global patent activity related to skin-barrier compositions increased substantially  during the past decade, rising from four published patents in 2014 to 263 patents in  2023, demonstrating growing investment in epidermal barrier technologies. 

Organizations actively filing patents related to skin longevity, neurocosmetics and  barrier science include LG Household & Healthcare, Lubrizol and TCI.

These activities indicate increasing industrial investment in skin resilience,  neurocutaneous biology and longevity-focused technologies. 

Formulation and Regulatory Considerations 

Successful menopause-focused formulations should balance efficacy with tolerability. Recommended pH ranges generally fall between 4.5 and 6.0, although active  stability requirements may influence formulation decisions. 

Leave-on emulsions and barrier-support creams may be particularly suitable for  xerotic skin, while lightweight serums may facilitate active layering. 

Retinoids are often better tolerated when combined with ceramides, glycerin or  squalane. Vitamin C derivatives may provide improved stability compared with L ascorbic acid. 

Patch testing, hydration studies, TEWL measurements and consumer tolerance  evaluations may strengthen product development and claim substantiation. 

Because certain ingredients may interact with hormone-related pathways,  formulators should avoid claims implying hormonal replacement or therapeutic  activity. 

Under European Cosmetics Regulation (EC) No. 1223/2009, cosmetic products must  avoid medicinal claims. Consequently, marketing language suggesting estrogen  replacement or systemic hormonal effects should be avoided. 

Claims should emphasize support of skin appearance, barrier function and skin  comfort rather than endocrine activity. 

Future Outlook 

Future menopause-focused formulations are likely to integrate barrier repair,  neurocutaneous signaling, circadian biology and skin longevity concepts within  multifunctional systems.

Rather than addressing isolated signs of aging, emerging approaches increasingly  focus on preserving skin function, maintaining epidermal resilience and supporting  long-term skin health throughout later life stages. 

Conclusion 

Menopausal skin represents a distinct biological and formulation challenge that  extends beyond conventional anti-aging approaches. Declining estrogen levels  influence barrier integrity, extracellular matrix maintenance, inflammatory signaling and skin resilience. 

Current evidence supports multifunctional strategies integrating barrier repair,  hydration, structural support and long-term skin health. Ceramides, niacinamide,  peptides, retinoids and antioxidants remain foundational technologies, while  emerging areas including neurocutaneous signalling, sleep-related repair and skin  longevity may shape future innovation. 

Although menopause-specific skincare innovation remains relatively limited,  advances in barrier science, skin-brain research and longevity-focused formulation  strategies provide important opportunities for the development of scientifically  substantiated products targeting menopausal skin. 

References 

1. Hall G, Phillips TJ. J Am Acad Dermatol. 2005;53(4):555–568. 

2. Stevenson S, Thornton J. Climacteric. 2007;10(4):289–297.  

3. Brincat MP. Maturitas. 2000;35(2):107–117.  

4. Verdier-Sévrain S, Bonté F. J Cosmet Dermatol. 2007;6(2):75–82. 

5. Proksch E, Brandner JM, Jensen JM. Exp Dermatol. 2008;17(12):1063–1072.  

6. Farage MA, Miller KW, Elsner P, Maibach HI. Int J Cosmet Sci. 2008;30(2):87–95.  

7. Shin JW, Kwon SH, Choi JY, et al. Int J Mol Sci. 2019;20(9):2126. 

8. Salem I, Ramser A, Isham N, Ghannoum MA. Microorganisms. 2018;6(1):14.  

9. Egert M, Simmering R. Adv Exp Med Biol. 2016;902:61–81.  

10. Krutmann J, Bouloc A, Sore G, Bernard BA, Passeron T. J Dermatol Sci. 2017;85(3):152–161.  

11. Proksch E. J Dermatol. 2018;45(9):1044–1052.  

12. Denda M, Tsutsumi M, Denda S. Exp Dermatol. 2010;19(11):873–878.  

13. Truong VL, Bak MJ, Lee C, Jun M, Jeong WS. Nutrients. 2021;13:1583.